Literature DB >> 32436120

A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases.

Winston Cai1, Andrew Cagan2, Zeling He3, Ashwin N Ananthakrishnan4,5.   

Abstract

INTRODUCTION: Crohn's disease (CD) and ulcerative colitis (UC) are associated with considerable direct healthcare costs. There have been few comprehensive analyses of all IBD- and non-IBD comorbidities that determine direct costs in this population.
METHODS: We used data from a validated cohort of patients with inflammatory bowel disease (IBD). Total healthcare costs were estimated as a sum of costs associated with IBD-related hospitalizations and surgery, imaging (CT or MR scans), outpatient visits, endoscopic evaluation, and emergency room (ER) care. All ICD-9 codes were extracted for each patient and clustered into 1804 distinct phecode clusters representing individual phenotypes. A phenome-wide association analysis (PheWAS) was performed using logistic regression to identify predictors of being in the top decile of costs.
RESULTS: Our cohort is comprised of 10,721 patients with IBD among whom 50% had CD. The median age was 46 years. The median total cost per patient is $11,203 (IQR $2396-30,563). The strongest association with total healthcare costs was intestinal obstruction without mention of hernia (p = 5.93 × 10-156) and other intestinal obstruction (p = 9.24 × 10-131). In addition, strong associations were observed for symptoms consistent with severity of IBD including the presence of fluid-electrolyte imbalance (p = 1.90 × 10-130), hypovolemia (p = 1.65 × 10-114), abdominal pain (p = 7.29 × 10-60), and anemia (p = 1.90-10-83). Cardiopulmonary diseases and psychological comorbidity also demonstrated significant associations with total costs with the latter being more strongly associated with ER visit-related costs.
CONCLUSIONS: Surrogate markers suggesting possible irreversible bowel damage and active disease demonstrate the greatest influence on IBD-related healthcare costs.

Entities:  

Keywords:  Cost; Crohn’s disease; Electronic health records; Ulcerative colitis

Year:  2020        PMID: 32436120     DOI: 10.1007/s10620-020-06329-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  3 in total

Review 1.  Diet in Treatment of Inflammatory Bowel Diseases.

Authors:  Alexa N Sasson; Ashwin N Ananthakrishnan; Maitreyi Raman
Journal:  Clin Gastroenterol Hepatol       Date:  2019-12-05       Impact factor: 11.382

Review 2.  Improving immunization strategies in patients with inflammatory bowel disease.

Authors:  Maham Farshidpour; Aline Charabaty; Mark C Mattar
Journal:  Ann Gastroenterol       Date:  2019-01-15

3.  Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins.

Authors:  Geert D'Haens; Orlaith Kelly; Robert Battat; Mark S Silverberg; David Laharie; Edouard Louis; Edoardo Savarino; Giorgia Bodini; Andres Yarur; Brigid S Boland; Waqqas Afif; Xiao-Jun Li; Michael Hale; Jessica Ho; Venkateswarlu Kondragunta; Benjamin Huang; Crystal Kuy; Lauren Okada; Kelly D Hester; Kurtis R Bray; Larry Mimms; Anjali Jain; Siddharth Singh; Angelina Collins; Mark A Valasek; William J Sandborn; Severine Vermeire; Parambir S Dulai
Journal:  Gastroenterology       Date:  2019-11-08       Impact factor: 22.682

  3 in total
  4 in total

Review 1.  Using Phecodes for Research with the Electronic Health Record: From PheWAS to PheRS.

Authors:  Lisa Bastarache
Journal:  Annu Rev Biomed Data Sci       Date:  2021-07-20

2.  Symptoms associated with healthcare resource utilization in the setting of inflammatory bowel disease.

Authors:  Kaleb Bogale; Parth Maheshwari; Mitchell Kang; Venkata Subhash Gorrepati; Shannon Dalessio; Vonn Walter; August Stuart; Walter Koltun; Nana Bernasko; Andrew Tinsley; Emmanuelle D Williams; Kofi Clarke; Matthew D Coates
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

3.  Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.

Authors:  Mohammad Zamani; Shaghayegh Alizadeh-Tabari; Siddharth Singh; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2022-03-11       Impact factor: 9.524

4.  Scanning the medical phenome to identify new diagnoses after recovery from COVID-19 in a US cohort.

Authors:  V Eric Kerchberger; Josh F Peterson; Wei-Qi Wei
Journal:  J Am Med Inform Assoc       Date:  2022-08-25       Impact factor: 7.942

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.